Literature DB >> 6688447

Endogenous ligand(s) decrease drug--protein binding in uremic sera: a fluorescence probe study.

G M Robertz, H J Dengler.   

Abstract

Human serum albumin (HSA) was isolated and purified (greater than 97% purity) from normal sera, from sera of patients with severe chronic renal insufficiency and from sera to which a strongly protein bound acidic drug--clofibrinic acid--was added as a model ligand. The binding properties were evaluated using dansylglycine as a fluorescent probe. Data were analyzed according to Scatchard, the binding constants were calculated by least square approximation. The binding of dansylglycine to HSA from uremic sera was substantially decreased, reflected mainly by a lower product n1 . K1, as was the binding of dansylglycine to HSA from model sera containing clofibrinic acid. The binding was restored to almost normal when HSA was treated with charcoal. It is concluded that the impaired binding of many mostly acidic drugs to HSA in uremia is due to the presence of endogenous ligands. In addition a minor contribution by changes in HSA structure cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6688447     DOI: 10.1007/bf01487581

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  19 in total

1.  THE ISOLATION OF SEVERAL AROMATIC ACIDS FROM THE HEMODIALYSIS FLUIDS OF UREMIC PATIENTS.

Authors:  B KRAMER; H SELIGSON; H BALTRUSH; D SELIGSON
Journal:  Clin Chim Acta       Date:  1965-04       Impact factor: 3.786

2.  Further characterization of specific drug binding sites on human serum albumin.

Authors:  G Sudlow; D J Birkett; D N Wade
Journal:  Mol Pharmacol       Date:  1976-11       Impact factor: 4.436

3.  Protein binding of salicylate in uremic and normal plasma.

Authors:  O Borgå; I O Cederlöf; V A Ringberger; A Norlin
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

4.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

5.  Influence of disease on binding of drugs to plasma proteins.

Authors:  M M Reidenberg; M Affrime
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

6.  The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.

Authors:  D W Shoeman; D L Azarnoff
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

7.  Plasma protein binding, plasma concentrations, and effects of diphenylhydantoin in man.

Authors:  L Lund; P K Lunde; A Rane; O Borga; F Sjöqvist
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

8.  Cooperative effects in binding by bovine serum albumin. I. The binding of 1-anilino-8-naphthalenesulfonate. Fluorimetric titrations.

Authors:  E Daniel; G Weber
Journal:  Biochemistry       Date:  1966-06       Impact factor: 3.162

9.  Plasma protein carbamylation and decreased acidic drug protein binding in uremia.

Authors:  S Erill; R Calvo; R Carlos
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

10.  Phenytoin binding to partially purified albumin in renal disease.

Authors:  D W Kinniburgh; N D Boyd
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

View more
  1 in total

1.  Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.

Authors:  F Keller; M Maiga; H H Neumayer; H Lode; A Distler
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.